H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Vertex Pharmaceuticals to $600 from $500 and keeps a Buy rating on the shares. The firm says an superior efficacy and safety profile of VX-880 differentiates it from the recently approved Lantidra.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $376 from $371 at Canaccord
- Vertex says FDA accepted suzetrigine new drug application
- Vertex Pharmaceuticals Inc. (VRTX) Q2 Earnings Cheat Sheet
- Vertex Pharmaceuticals price target raised to $500 from $462 at H.C. Wainwright
- Vertex Pharmaceuticals expands drug discovery collaboration with Genomics